PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “ERYTHEMA INFECTIOSUM”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 505 records · Page 28Linked to original sources

Papular-purpuric "gloves and socks" syndrome: polymerase chain reaction demonstration of parvovirus B19 DNA in cutaneous lesions and sera.

We report a typical case of papular-purpuric "gloves and socks" syndrome (PPGSS) in which primary infection by parvovirus B19 was demonstrated by seroconversion to this virus; parvovirus B19 DNA was also identified by polymerase chain reaction (PCR) methods in the sera of the patient and in the cutaneous biopsy specimen, both taken 4 days after the onset of clinical manifestations. To our knowledge, this is the fourth published case in which parvovirus B19 DNA has been recovered from the skin by PCR. Serologic studies and PCR investigations in cutaneous biopsy for other viruses including herpes simplex virus types 1 and 2, varicella zoster virus, Epstein-Barr virus, cytomegalovirus, and human herpesvirus 6, 7, and 8 were negative. Clinically, our case presented some additional features, which have not been previously described in cases of PPGSS, namely dysuria with vulvar edema and erythema, and unilateral petechial rash on the breast. The histopathologic findings of our case were nonspecific and consisted of an interface dermatitis with slight vacuolar degeneration at the dermoepidermal junction and a superficial perivascular inflammatory infiltrate mostly composed of lymphocytes, with numerous extravasated erythrocytes. We review the cases of PPGSS published in the literature with respect to the different viruses that have been proposed as etiologic agents and conclude that acute infection by parvovirus B19 is the only one that has been adequately proved.

Adult↗

[Outbreak of infectious erythema at a urban health center].

OBJECTIVES: To analyse the clinical and serological characteristics of an outbreak of infectious erythema in patients attending the two paediatrics clinics at the Soria Norte Health Centre. DESIGN: Cross-sectional, descriptive study. SETTING: Paediatrics clinics of the Soria Norte Health Centre. PATIENTS: Once the outbreak was suspected, the study was conducted on children with a clinical picture suggesting infectious erythema who attended successively two Soria Norte paediatrics clinics between April and August 1998 and who consented to the analyses. INTERVENTIONS: The clinical symptoms, serology, haemogram and evolution of 25 patients were recorded. RESULTS: 25 patients of the total were studied and diagnostic suspicion was confirmed in 84% of the cases. There were no differences between sexes, with an average age of 6.1, SD 2.015. The most constant clinical sign was exanthem on the cheeks, present in 100% of the cases confirmed, followed by 57% exanthem on the trunk and limbs, 9.5% adenopathies and 4.7% temperature. No complications were found in any case. CONCLUSIONS: The results of this study confirm the existence of an outbreak of infectious erythema in our area. Serological confirmation of an outbreak is useful and can lay the basis for a proper therapeutic and preventive focus (against possible complications). We highlight the generally benign nature of the disease.

Child↗

[Acute transitory intrafamilial erythroblastopenia and hereditary spherocytosis: role of parvovirus B19].

INTRODUCTION: Acute parvovirus B19 infection induces a transient inhibition of erythroid cell formation, which may induce an erythroblastopenia crisis in patients suffering from chronic hemolytic anemia. EXEGESIS: We report here an exceptional observation of acute erythroblastopenia crisis with good outcome, occurring at the same time in a mother and her son, both suffering from hereditary spherocytosis. Diagnosis of parvovirus infection is based on detection of serum parvovirus B19-specific immunoglobulin M antibodies in the mother and her son and by the positivity of parvovirus B19 DNA detected by PCR in serum in the mother. Outcome was good, with the end of the erythroblastopenia crisis obtained 7 to 10 days later, but requiring blood transfusion in the mother. CONCLUSION: Our observation is a reminder that the contagiosity of parvovirus B19 is high in household contacts and that protection of family members should rapidly be considered in hereditary spherocytosis.

Acute Disease↗

[Joint manifestations and parvovorus B19 infections: 8 cases].

Human Parvovirus B19 (PB19) may cause joint manifestations. We report eight cases of polyarthritis associated with PB19 IgM: six cases of acute polyarthritis spontaneously resolving within a few days, and two other cases suggesting that PB19 should be responsible for accutisation of chronic disease (lupus with Kikuchi's disease and HLA B27 related arthritis).

Adult↗

[Periarteritis nodosa and parvovirus B19 infection].

The authors report a case of polyarteritis nodosa which coincide with serological conversion to parvovirus B19. After review of the literature, they recall the role of this virus in human pathology and also the role of different infectious agents in the PAN pathogenesis.

Aged↗

Human parvovirus B19: immunity of Greek females and prenatal investigation of hydrops fetalis.

Sera from 308 healthy Greek females of reproductive age were examined for specific IgG antibodies to human parvovirus B19 by recombinant-Elisa to determine the immunity rates of this part of population to parvovirus B19. Also paired maternal sera and amniotic fluids from nine pregnancies with hydrops fetalis were investigated for specific IgG and IgM antibodies and parvovirus DNA by polymerase chain reaction and southern hybridization analysis. The latter study was conducted to find out the participation of parvovirus B19 infection in hydrops fetalis cases in Greece. The overall prevalence of IgG antibodies in healthy Greek females was at a rate of 57.8% rising with age. One case of hydrops fetalis out of the nine examined, was diagnosed prenatally as parvovirus B19 maternal-fetal infection. It was a twin pregnancy with one fetus hydropic and the other growth retarded. Premature birth of liveborn infants was followed by neonatal death, 48 h after delivery. The contribution of parvovirus B19 in cases of non-immune hydrops fetalis was at 11% in this part of the world.

Adult↗

Parvoviruses and blood products.

Erythrovirus B19 (B19), a small isocahedral, non-enveloped virus (18-26 nm), is a ubiquitous infection agent in industrialised countries. Depending on the infected host, B19 has a wide range of disease manifestations from asymptomatic (the majority) to severe, including persistent infection. The risk of B19 transmission by blood products is enhanced by a high virus titre in the infected donor, by pooling of a large number of donations, and by the virus's resistance to effective inactivation methods such as heat and solvent-detergent treatments. B19-DNA has been detected in single donations, in manufacture plasma pools and in plasma derivatives (clotting factors, albumin, antithrombin III and immunoglobulins) produced by different processes. B19 transmission is mostly found in patients treated with clotting factors, as shown by a higher seroprevalence in treated haemophiliacs, by the presence of B19 DNA, and by active seroconversion. Chronic B19 infection can successfully be treated with polyvalent intravenous immunoglobulins. The key role of neutralising anti-B19 antibodies and of the virus titre has been demonstrated by B19 transmission after infusion of several B19-positive plasma batches treated with solvent-detergent. Two strategies can be followed to reduce the B19 risk: (1) reducing the viral load in the manufacture plasma pool by discarding B19-DNA-positive donations; (2) developing new strong virus inactivation methods. The physico-resistant properties of B19 make it a good model for new emergent viruses capable of infecting blood products.

Antibodies, Viral↗

Dot-blot hybridisation assay for detection of parvovirus B19 infections using synthetic oligonucleotides.

Pools of 10 synthetic oligonucleotides with sequences derived from the genome of parvovirus B19 and of 30 bases in length were made and labelled at the time of synthesis with digoxigenin (DIG) or dinitrophenyl (DNP) at the 5' end. They were used in a dot-blot hybridisation assay to detect parvovirus B19 DNA in sera submitted for routine virological diagnosis where parvovirus infection was suspected. Detection down to 10-100 fg DNA (equivalent to 10(3)-10(4) copies of parvovirus B19 genome) was obtained with both probe cocktails and colorimetric or chemiluminescent detection systems. Of 141 clinical samples examined from 126 patients presenting with rash and/or joint pains, 107 were clearly negative with both probes, 20 were clearly positive and the remaining 14 samples gave discrepant results. Of these 34 samples, 33 contained parvovirus B19 specific IgM. The parvovirus oligonucleotide probe cocktail produced and labelled with either DIG or DNP provided a useful diagnostic reagent for the detection of specific DNA in clinical specimens using a simple and sensitive dot-blot assay.

Adult↗

Toxoplasmosis and parvovirus B19.

Pregnant women might well improve their chances for a successful pregnancy outcome by following the advice of W. C. Fields: avoid contact with small children and animals whenever possible. Failing widespread acceptance of this philosophy, management of T. gondii and parvovirus B19 infections continues to be a challenge for the foreseeable future.

Erythema Infectiosum↗

A recombinant immunoblot and ELISA for detection of acute parvovirus B19 infection.

Laboratory diagnosis of parvovirus B19 (B19) infection has been hampered by the limited availability of B19 virus. Recombinant viral proteins are now available for use as antigen in serological assays. We compared detection of anti-B19 IgM by "mu-capture assay" using viral B19 particles to a recombinant (rec.) immunoblot and a rec. enzyme-immunoassay (ELISA) using viral structural proteins as antigens expressed in E. coli. The rec. immunoblot was 94.3% sensitive and 96.4% specific for anti-B19 IgM, and the sensitivity of the rec. ELISA was 94.3% and the specificity, only 72.7%. There was an agreement between the "mu-capture assay" and the rec. immunoblot in 87.8% and the rec. ELISA in only 74.4%. For detection of anti-B19 IgG in patients with acute B19 infection, the rec. immunoblot was 94.3% and the rec. ELISA 85.7% sensitive. The rec. immunoblot is more reliable for detection of acute B19 infection than the rec. ELISA.

Antibodies, Viral↗

Prevalence of antibodies to parvovirus B19 in selected groups of patients and healthy individuals.

The prevalence of antibodies to parvovirus B19 in sera (n = 745) of various groups of patients and healthy individuals was determined by the enzyme immunoassay, using viral particles as antigen. Among healthy individuals, anti-B19 IgG prevalence was highest in nurses (65.4% (17/26)); in medical students it was 34.1% (47/138) and in pregnant females, 24.4% (48/197). 37.0% (44/119) of HIV-negative haemophiliac patients and 91.7% (33/36) of haemophilic patients with HIV infection were anti-B19 IgG-positive. 45.8% (55/120) of dialysis patients and 27.5% (30/109) of patients with asymptomatic HIV infection were positive for anti-B19 IgG. With the exception of HIV-infected haemophiliac patients, no specific "risk group" for B19 infection could be identified.

Adolescent↗

B19 parvovirus.

B19 parvovirus is pathogenic in man and causes a variety of clinical illnesses, among them several haematological diseases. Acute infection of a host with underlying haemolysis produces transient aplastic crisis; of the midtrimester fetus, hydrops fetalis; and of an immunocompromised patient, pure red cell aplasia. The target of B19 parvovirus infection is the human erythroid progenitor cell. Infection is cytotoxic due to expression of the viral nonstructural protein. The virus can be propagated in cultures of human bone marrow, blood, and fetal liver. Humoral immunity normally terminates infection, and commercially available immunoglobulin can be used to treat persistent infection. Recombinant capsids, produced in a baculovirus system, are suitable as a vaccine reagent.

Adult↗